Zobrazeno 1 - 10
of 79
pro vyhledávání: '"Boris Klebanov"'
Autor:
Stephen Sazinsky, Mohammad Zafari, Boris Klebanov, Jessica Ritter, Phuong A. Nguyen, Ryan T. Phennicie, Joe Wahle, Kevin J. Kauffman, Maja Razlog, Denise Manfra, Igor Feldman, Tatiana Novobrantseva
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 11, p 6160 (2024)
V-set immunoglobulin domain-containing 4 (VSIG4) is a B7 family protein with known roles as a C3 fragment complement receptor involved in pathogen clearance and a negative regulator of T cell activation by an undetermined mechanism. VSIG4 expression
Externí odkaz:
https://doaj.org/article/33014c3e01f24cff8098a8c9257afb56
Autor:
Jessica D. Weaver, Edward C. Stack, Joshua A. Buggé, Changyun Hu, Lara McGrath, Amy Mueller, Masie Wong, Boris Klebanov, Tanzila Rahman, Rosemary Kaufman, Christine Fregeau, Vikki Spaulding, Michelle Priess, Kristen Legendre, Sarah Jaffe, Dhruvkumar Upadhyay, Anirudh Singh, Chang-Ai Xu, Kristin Krukenberg, Yan Zhang, Yassine Ezzyat, Dorothée Saddier Axe, Michelle R. Kuhne, Michael A. Meehl, Donald R. Shaffer, Brian M. Weist, Dmitri Wiederschain, Fabien Depis, Monica Gostissa
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
The presence of T regulatory (Treg) cells in the tumor microenvironment is associated with poor prognosis and resistance to therapies aimed at reactivating anti-tumor immune responses. Therefore, depletion of tumor-infiltrating Tregs is a potential a
Externí odkaz:
https://doaj.org/article/9a4049560acc4a71971464efbe2cc5d2
Autor:
Phuong Nguyen, Igor Feldman, Mohammad Zafari, Ryan Phennicie, Veronica Komoroski, Steve Sazinsky, Joe Wahle, Denise Manfra, Tatiana Novobrantseva, Kathryn Rooney, Craig Mizzoni, Boris Klebanov, Jessica Ritter
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/e697faf2efcc4f60b58a0a4e77f66798
Autor:
Tatiana I Novobrantseva, Anna Borodovsky, Jamie Wong, Boris Klebanov, Mohammad Zafari, Kristina Yucius, William Querbes, Pei Ge, Vera M Ruda, Stuart Milstein, Lauren Speciner, Rick Duncan, Scott Barros, Genc Basha, Pieter Cullis, Akin Akinc, Jessica S Donahoe, K Narayanannair Jayaprakash, Muthusamy Jayaraman, Roman L Bogorad, Kevin Love, Katie Whitehead, Chris Levins, Muthiah Manoharan, Filip K Swirski, Ralph Weissleder, Robert Langer, Daniel G Anderson, Antonin de Fougerolles, Matthias Nahrendorf, Victor Koteliansky
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 1, Iss C (2012)
Leukocytes are central regulators of inflammation and the target cells of therapies for key diseases, including autoimmune, cardiovascular, and malignant disorders. Efficient in vivo delivery of small interfering RNA (siRNA) to immune cells could thu
Externí odkaz:
https://doaj.org/article/31889f2554494de9a6c937025cd1946a
Autor:
Stephanie K. Dougan, Michael Dougan, Yosef Landesman, Sharon Sacham, Trinayan Kashyap, Boris Klebanov, Romy C. de Vries, Mariah M. Servos, Paul M. Tyler
Supplemental Figure 1: Response to immunization is only modestly affected by selinexor.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7e3dd2782c79ebaa858be1024365729
https://doi.org/10.1158/1535-7163.22509346
https://doi.org/10.1158/1535-7163.22509346
Autor:
Gregory B. Lesinski, Christin E. Burd, Trinayan Kashyap, Boris Klebanov, Marsha Crochiere, Sivan Elloul, Yosef Landesman, Kari Kendra, Gregory Young, Omar Elnaggar, Reena Shakya, Rebecca C. Hennessey, Matthew R. Farren
Selinexor, a selective inhibitor of nuclear export (SINE) compound targeting exportin-1, has previously been shown to inhibit melanoma cell growth in vivo. We hypothesized that combining selinexor with antibodies that block or disrupt T-cell checkpoi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61e518810db0529b9a40a9c84db1b373
https://doi.org/10.1158/1535-7163.c.6539550
https://doi.org/10.1158/1535-7163.c.6539550
Autor:
Gregory B. Lesinski, Christin E. Burd, Trinayan Kashyap, Boris Klebanov, Marsha Crochiere, Sivan Elloul, Yosef Landesman, Kari Kendra, Gregory Young, Omar Elnaggar, Reena Shakya, Rebecca C. Hennessey, Matthew R. Farren
Supplemental Figure S1: Effects of alternative dosing schedules for selinexor (15 mg/kg) and anti-PD-1 on systemic immune populations; Supplemental Figure S2: Effects of alternative dosing schedules for selinexor (10 mg/kg) and anti-PD-1 on systemic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b62759dda4e94d4aa77a8456db24faaf
https://doi.org/10.1158/1535-7163.22510242
https://doi.org/10.1158/1535-7163.22510242
Autor:
Stephanie K. Dougan, Michael Dougan, Yosef Landesman, Sharon Sacham, Trinayan Kashyap, Boris Klebanov, Romy C. de Vries, Mariah M. Servos, Paul M. Tyler
Supplemental Figure 3: Degranulation of effector CD8 T cells is affected by selinexor.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a22bc7dcb83589955473e577e58b61a
https://doi.org/10.1158/1535-7163.22509340.v1
https://doi.org/10.1158/1535-7163.22509340.v1
Autor:
Stephanie K. Dougan, Michael Dougan, Yosef Landesman, Sharon Sacham, Trinayan Kashyap, Boris Klebanov, Romy C. de Vries, Mariah M. Servos, Paul M. Tyler
Supplemental Figure 2: IFNγ secretion is impaired by selinexor.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1240f94ccb7d588d494dd8aa1380214
https://doi.org/10.1158/1535-7163.22509343.v1
https://doi.org/10.1158/1535-7163.22509343.v1
Autor:
Stephanie K. Dougan, Michael Dougan, Yosef Landesman, Sharon Sacham, Trinayan Kashyap, Boris Klebanov, Romy C. de Vries, Mariah M. Servos, Paul M. Tyler
Selinexor (KPT-330) is a first-in-class nuclear transport inhibitor currently in clinical trials as an anticancer agent. To determine how selinexor might affect antitumor immunity, we analyzed immune homeostasis in mice treated with selinexor and fou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::32ca42473c520b40f0072488fdabd409
https://doi.org/10.1158/1535-7163.c.6539275.v1
https://doi.org/10.1158/1535-7163.c.6539275.v1